(0.07%) 5 521.00 points
(0.11%) 39 888 points
(0.19%) 19 788 points
(0.00%) $81.63
(0.43%) $2.82
(-0.32%) $2 336.90
(0.00%) $29.53
(0.27%) $1 004.50
(0.03%) $0.932
(0.03%) $10.54
(0.01%) $0.788
(-2.06%) $86.18
0.00% $ 0.0701
Live Chart Being Loaded With Signals
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases...
Stats | |
---|---|
Dzisiejszy wolumen | 8.56M |
Średni wolumen | 0 |
Kapitalizacja rynkowa | 0.00 |
EPS | $-0.340 ( Q2 | 2022-08-12 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.0300 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0750 (106.99%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-05-19 | Van Den Broek Richard | Buy | 3 750 | Common Stock |
2023-05-19 | Van Den Broek Richard | Sell | 3 750 | Restricted Stock Units |
2023-05-19 | Thorp Clay | Buy | 3 750 | Common Stock |
2023-05-19 | Thorp Clay | Buy | 3 750 | Restricted Stock Units |
2023-05-19 | Humphries William D. | Buy | 2 538 | Common Stock |
INSIDER POWER |
---|
-91.60 |
Last 98 transactions |
Buy: 2 306 852 | Sell: 1 915 751 |
Wolumen Korelacja
PhaseBio Pharmaceuticals, Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
PhaseBio Pharmaceuticals, Korelacja - Waluta/Towar
PhaseBio Pharmaceuticals, Finanse
Annual | 2021 |
Przychody: | $10 831.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-0.00446 |
FY | 2021 |
Przychody: | $10 831.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-0.00446 |
FY | 2020 |
Przychody: | $320 000 |
Zysk brutto: | $320.00 (0.10 %) |
EPS: | $-3.39 |
FY | 2019 |
Przychody: | $2.36M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-1.430 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
PhaseBio Pharmaceuticals,
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej